Head and Neck Carcinoma Clinical Trials & Research at St. Joseph Health Medical Group

Head and neck cancers start in the tissues and organs of the head and neck and include cancers of the larynx (voice box), throat, lips, mouth, nose, and salivary glands. Most head and neck cancers are squamous cell carcinomas and begin in the moist tissues that line the mouth, nose and throat. Tobacco use, heavy alcohol use, and infection with the human papillomavirus (HPV) increase your risk of head and neck cancer.

St. Joseph Health Medical Group is currently enrolling patients for the following head and neck carcinoma clinical trial:

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-689)

Phase III

This is a study of pembrolizumab as neoadjuvant therapy and pembrolizumab in combination with standard of care radiation therapy with/without cisplatin as post-surgical adjuvant therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable locoregionally advanced head and neck squamous cell carcinoma.

Treatment agent: Pembrolizumab + stadard of care radiotion therapy
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03765918

A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)

Phase III

The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma. The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival.

Treatment agent: Pembrolizumab
PI: Thomas Stanton, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03428217

Our Locations